Questionable pooling of data.
作者信息
Schenk Stefanie
出版信息
Dtsch Arztebl Int. 2015 Mar 20;112(12):209-10. doi: 10.3238/arztebl.2015.0209b.
Abstract
摘要
相似文献
1
Questionable pooling of data.可疑的数据合并。
Dtsch Arztebl Int. 2015 Mar 20;112(12):209-10. doi: 10.3238/arztebl.2015.0209b.
2
In reply.作为答复。
Dtsch Arztebl Int. 2015 Mar 20;112(12):210. doi: 10.3238/arztebl.2015.0210.
3
Unethical approach.不道德的方法。
Dtsch Arztebl Int. 2015 Mar 20;112(12):209. doi: 10.3238/arztebl.2015.0209a.
4
Asia Pacific: cervical cancer screening and human papillomavirus vaccination policy and delivery.亚太地区：宫颈癌筛查与人乳头瘤病毒疫苗接种政策及实施情况
Vaccine. 2008 Aug 19;26 Suppl 12(Suppl 12):iii-iv. doi: 10.1016/j.vaccine.2008.06.033.
5
Prophylactic HPV vaccination for the prevention of cervical cancer.预防性人乳头瘤病毒疫苗用于预防宫颈癌。
Hawaii Med J. 2007 Jul;66(7):190-1.
6
HPV vaccination: Clinical potential, implementation challenges, and future directions.人乳头瘤病毒疫苗接种：临床潜力、实施挑战及未来方向。
Hum Vaccin Immunother. 2016 Jun 2;12(6):1327-31. doi: 10.1080/21645515.2016.1177680.
7
HPV vaccination in Southern Africa: A jab of hope in the fight against cervical cancer.南非的人乳头瘤病毒疫苗接种：抗击宫颈癌的一剂希望之针。
Cancer Cytopathol. 2016 Oct;124(10):695-698. doi: 10.1002/cncy.21738. Epub 2016 May 16.
8
[Cervix carcinoma--Austrian Vaccination Committee recommends HPV vaccination].子宫颈癌——奥地利疫苗接种委员会建议接种人乳头瘤病毒疫苗
Wien Med Wochenschr. 2007;157(5-6):130-2. doi: 10.1007/s10354-007-0395-9.
9
Experts say that cervical cancer could be eliminated worldwide with screening, human papillomavirus vaccine.专家表示，通过筛查和人乳头瘤病毒疫苗，宫颈癌在全球范围内是可以消除的。
Cancer. 2020 Aug 1;126(15):3387. doi: 10.1002/cncr.33070.
10
Human papillomavirus vaccine for cancer cervix prevention: Rationale & recommendations for implementation in India.用于预防宫颈癌的人乳头瘤病毒疫苗：原理及在印度实施的建议
Indian J Med Res. 2017 Aug;146(2):153-157. doi: 10.4103/ijmr.IJMR_1906_16.
本文引用的文献
1
The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis.人乳头瘤病毒疫苗保护的效力和持续时间：一项系统评价与荟萃分析
Dtsch Arztebl Int. 2014 Sep 1;111(35-36):584-91. doi: 10.3238/arztebl.2014.0584.
2
Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial.人乳头瘤病毒 16/18 型 AS04 佐剂疫苗在 20 至 25 岁日本女性中的效力：一项 2 期双盲、随机对照临床试验的最终分析。
Int J Gynecol Cancer. 2010 Jul;20(5):847-55. doi: 10.1111/IGC.0b013e3181da2128.
3
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.人乳头瘤病毒（HPV）-6/11/16/18 疫苗对年轻女性所有 HPV 相关生殖器疾病的影响。
J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.
4
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.一种预防性四价人乳头瘤病毒6/11/16/18型L1病毒样颗粒疫苗在长达5年的随访期内具有高持续效力。
Br J Cancer. 2006 Dec 4;95(11):1459-66. doi: 10.1038/sj.bjc.6603469. Epub 2006 Nov 21.
Zotero 插件